SOD1 and Parkinson disease: Similar to current clinical trials of CuII(atsm) in ALS, there are no outcome measures quantifying SOD1 metalation, protein levels or catalytic activity in the current trial of CuII(atsm) in Parkinson's disease due to the likely restriction of SOD1 mismetalation to central nervous system tissue.